Multiple Sclerosis Therapy Stops Linked to Disability
A meta-analysis of 36,681 patients shows that discontinuing disease-modifying therapies is tied to disease reactivation.
Updated on Oct. 20, 2026 in Stroke
Live Poll
Do you believe patient preference should outweigh clinical monitoring when managing long-term treatment plans?
A systematic review of 33 studies published in October 2025 reveals that halting multiple sclerosis treatments is associated with higher disability scores and increased disease activity. The research highlights the clinical risks associated with stopping these therapies for thousands of patients.
Why it matters
The findings underscore the significant impact that treatment interruptions have on long-term patient health and neurological stability. Understanding the drivers behind discontinuation is vital for clinicians managing the disease.
A meta-analysis of 33 studies involving 36,681 patients found that 22% of those who stopped treatment experienced MRI-detected disease reactivation. Patients who discontinued therapy also showed a pooled mean difference in EDSS scores of 0.55.
The players
MSToronto2026
This upcoming medical conference serves as the venue for presenting the latest research on multiple sclerosis treatment outcomes.
The details
Researchers determined that safety concerns were the primary driver for stopping therapy, accounting for 32% of cases, followed by patient preference at 22%. While 50% of patients eventually resumed their medication, female sex was identified as a statistically significant predictor for choosing to discontinue treatment.
Timeline
The database search period for the studies concluded in October 2025.
Results are scheduled for presentation at MSToronto2026 from October 21 to 23, 2026.
The Big Picture
This study follows a pattern set by the ACTRIMS-ECTRIMS international conference series in prioritizing global collaborative data. By pooling outcomes from 33 studies, the meta-analysis bridges disparate regional findings to establish a clearer baseline for treatment discontinuation risks.
Patients and clinicians can use this data to better evaluate the risks of pausing or switching disease-modifying therapies for multiple sclerosis. The findings emphasize that treatment adherence is closely tied to managing disability and preventing disease reactivation.
The takeaway
Patients considering a break from their multiple sclerosis medication should engage in detailed discussions with their neurologists regarding potential disease reactivation. Balancing safety concerns against the clear clinical risk of increased disability is essential for maintaining neurological health.
What happens next
The findings are scheduled to be formally presented at the MSToronto2026 conference occurring from October 21 to 23, 2026.
Further reading
Learn more about neurological conditions and care options at the Stroke section.
Live Poll
Do you believe patient preference should outweigh clinical monitoring when managing long-term treatment plans?
